Cargando…

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience

INTRODUCTION: We aimed to evaluate real-life experiences with the re-challenge of poly(ADP-Ribose)Polymerase (PARP) inhibitors (PARPi) after a prior PARPi therapy in patients with recurrent EOC. METHODS: A retrospective descriptive study was conducted at a tertiary care center of excellence for ovar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moubarak, Malak, Harter, Philipp, Ataseven, Beyhan, Traut, Alexander, Welz, Julia, Baert, Thais, Heitz, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829558/ https://www.ncbi.nlm.nih.gov/pubmed/35169607 http://dx.doi.org/10.1016/j.gore.2022.100939

Ejemplares similares

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
por: Imterat, Majdi, et al.
Publicado: (2023)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer
por: Heitz, Florian, et al.
Publicado: (2023)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors
por: Plett, Helmut, et al.
Publicado: (2020)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)
por: Fotopoulou, Christina, et al.
Publicado: (2021)

The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)
por: Rose, Peter G, et al.
Publicado: (2021)

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes
por: Todisco, Elisabetta, et al.
Publicado: (2022)

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
por: Li, Lei, et al.
Publicado: (2023)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
por: Vos, Janet R, et al.
Publicado: (2019)

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
por: Cao, Qi, et al.
Publicado: (2023)

Discriminating radiation injury from recurrent tumor with [(18)F]PARPi and amino acid PET in mouse models
por: Donabedian, Patrick L., et al.
Publicado: (2018)

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer
por: Heitz, Florian, et al.
Publicado: (2022)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
por: O’Sullivan, Julia, et al.
Publicado: (2023)

Early-stage epithelial ovarian cancer: is systematic lymph node staging mandatory?
por: Imterat, Majdi, et al.
Publicado: (2021)

Ovarian cancer and the immune system
por: Baert, Thaïs, et al.
Publicado: (2017)

Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer
por: Herold, Natalie, et al.
Publicado: (2023)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
por: Reinisch, Mattea, et al.
Publicado: (2023)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020)

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
por: Bruzas, Simona, et al.
Publicado: (2021)

Different TP53 mutants in p53 overexpressed epithelial ovarian carcinoma can be associated both with altered and unaltered glycolytic and apoptotic profiles
por: Antoun, Stephanie, et al.
Publicado: (2018)

Low E2F2 activity is associated with high genomic instability and PARPi resistance
por: Rennhack, Jonathan P., et al.
Publicado: (2020)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7j86trhof1dt6v7sempacl2979